Developing best-in-class precision gene editing platforms to improve the safety and efficacy of CRISPR therapeutics.
Acrigen Biosciences
Platform/Neurology
Total Addressable Market
$10 billion+
Red Tree Board Member(s)
Red Tree Board Member
Heath Lukatch, Ph.D. (board chairman)
Red Tree Board Observer
Jennifer Cochran, Ph.D.
Red Tree Participation
Led seed round
